NO964517L - Anvendelse av et salt for fremstilling av et kosmetisk, dermatologisk eller farmasöytisk preparat, preparatet som sådan samt fremgangsmåte for kosmetisk behandling - Google Patents

Anvendelse av et salt for fremstilling av et kosmetisk, dermatologisk eller farmasöytisk preparat, preparatet som sådan samt fremgangsmåte for kosmetisk behandling Download PDF

Info

Publication number: NO964517L
Authority: NO; Norway
Prior art keywords: preparation; agents; cosmetic; stated; skin
Prior art date: 1995-10-26

Application number

NO964517A

Other languages

English (en)

Norwegian (no)

Other versions

NO964517D0 (no

Inventor

Olivier De Lacharriere

Lionel Breton

Original Assignee

Oreal

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-26

Filing date

1996-10-24

Publication date

1997-04-28

1996-10-24 Application filed by Oreal filed Critical Oreal

1996-10-24 Publication of NO964517D0 publication Critical patent/NO964517D0/no

1997-04-28 Publication of NO964517L publication Critical patent/NO964517L/no

Links

238000002360 preparation method Methods 0.000 title claims abstract description 74
239000002537 cosmetic Substances 0.000 title claims abstract description 38
150000003839 salts Chemical class 0.000 title claims abstract description 36
238000000034 method Methods 0.000 title claims description 8
239000008194 pharmaceutical composition Substances 0.000 title 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims abstract description 19
239000003890 substance P antagonist Substances 0.000 claims abstract description 19
229910052718 tin Inorganic materials 0.000 claims abstract description 17
230000000622 irritating effect Effects 0.000 claims abstract description 16
239000000203 mixture Substances 0.000 claims abstract description 12
229910052779 Neodymium Inorganic materials 0.000 claims abstract description 9
QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims abstract description 9
229910052727 yttrium Inorganic materials 0.000 claims abstract description 8
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims abstract description 8
229910052688 Gadolinium Inorganic materials 0.000 claims abstract description 7
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims abstract description 7
229910052692 Dysprosium Inorganic materials 0.000 claims abstract description 5
229910052691 Erbium Inorganic materials 0.000 claims abstract description 5
229910052693 Europium Inorganic materials 0.000 claims abstract description 5
229910052689 Holmium Inorganic materials 0.000 claims abstract description 5
229910052765 Lutetium Inorganic materials 0.000 claims abstract description 5
229910052777 Praseodymium Inorganic materials 0.000 claims abstract description 5
229910052773 Promethium Inorganic materials 0.000 claims abstract description 5
229910052772 Samarium Inorganic materials 0.000 claims abstract description 5
229910052771 Terbium Inorganic materials 0.000 claims abstract description 5
229910052775 Thulium Inorganic materials 0.000 claims abstract description 5
229910052769 Ytterbium Inorganic materials 0.000 claims abstract description 5
KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims abstract description 5
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims abstract description 5
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims abstract description 5
KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims abstract description 5
229910052746 lanthanum Inorganic materials 0.000 claims abstract description 5
FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims abstract description 5
OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims abstract description 5
PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 claims abstract description 5
VQMWBBYLQSCNPO-UHFFFAOYSA-N promethium atom Chemical compound [Pm] VQMWBBYLQSCNPO-UHFFFAOYSA-N 0.000 claims abstract description 5
KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims abstract description 5
GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims abstract description 5
NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims abstract description 5
229910052684 Cerium Inorganic materials 0.000 claims abstract description 4
GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 claims abstract 3
230000037307 sensitive skin Effects 0.000 claims description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
239000003795 chemical substances by application Substances 0.000 claims description 19
208000035475 disorder Diseases 0.000 claims description 19
208000003251 Pruritus Diseases 0.000 claims description 18
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 16
150000003746 yttrium Chemical class 0.000 claims description 16
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims description 15
101800003906 Substance P Proteins 0.000 claims description 15
239000000825 pharmaceutical preparation Substances 0.000 claims description 14
208000002193 Pain Diseases 0.000 claims description 13
239000013543 active substance Substances 0.000 claims description 11
210000004209 hair Anatomy 0.000 claims description 11
206010015150 Erythema Diseases 0.000 claims description 10
206010061218 Inflammation Diseases 0.000 claims description 10
230000004054 inflammatory process Effects 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
230000035807 sensation Effects 0.000 claims description 10
208000010668 atopic eczema Diseases 0.000 claims description 9
231100000321 erythema Toxicity 0.000 claims description 9
-1 nitrate ions Chemical class 0.000 claims description 8
206010013886 Dysaesthesia Diseases 0.000 claims description 7
230000036407 pain Effects 0.000 claims description 7
208000035824 paresthesia Diseases 0.000 claims description 7
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
230000000172 allergic effect Effects 0.000 claims description 6
239000005557 antagonist Substances 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 6
210000004400 mucous membrane Anatomy 0.000 claims description 6
208000017520 skin disease Diseases 0.000 claims description 6
238000003786 synthesis reaction Methods 0.000 claims description 6
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims description 5
150000007513 acids Chemical class 0.000 claims description 5
210000003169 central nervous system Anatomy 0.000 claims description 5
210000002966 serum Anatomy 0.000 claims description 5
208000001840 Dandruff Diseases 0.000 claims description 4
208000010201 Exanthema Diseases 0.000 claims description 4
239000003242 anti bacterial agent Substances 0.000 claims description 4
239000003096 antiparasitic agent Substances 0.000 claims description 4
201000005884 exanthem Diseases 0.000 claims description 4
210000004392 genitalia Anatomy 0.000 claims description 4
206010037844 rash Diseases 0.000 claims description 4
102000008186 Collagen Human genes 0.000 claims description 3
108010035532 Collagen Proteins 0.000 claims description 3
206010016654 Fibrosis Diseases 0.000 claims description 3
208000018522 Gastrointestinal disease Diseases 0.000 claims description 3
102000000589 Interleukin-1 Human genes 0.000 claims description 3
208000012641 Pigmentation disease Diseases 0.000 claims description 3
150000001413 amino acids Chemical class 0.000 claims description 3
239000000058 anti acne agent Substances 0.000 claims description 3
229940124340 antiacne agent Drugs 0.000 claims description 3
229940121375 antifungal agent Drugs 0.000 claims description 3
239000003429 antifungal agent Substances 0.000 claims description 3
229940125687 antiparasitic agent Drugs 0.000 claims description 3
239000003443 antiviral agent Substances 0.000 claims description 3
229920001436 collagen Polymers 0.000 claims description 3
230000004069 differentiation Effects 0.000 claims description 3
239000006185 dispersion Substances 0.000 claims description 3
235000013399 edible fruits Nutrition 0.000 claims description 3
239000000284 extract Substances 0.000 claims description 3
230000004761 fibrosis Effects 0.000 claims description 3
239000003193 general anesthetic agent Substances 0.000 claims description 3
229960001340 histamine Drugs 0.000 claims description 3
208000026278 immune system disease Diseases 0.000 claims description 3
239000003410 keratolytic agent Substances 0.000 claims description 3
230000035755 proliferation Effects 0.000 claims description 3
208000023504 respiratory system disease Diseases 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
241001113425 Iridaceae Species 0.000 claims description 2
208000016222 Pancreatic disease Diseases 0.000 claims description 2
206010040880 Skin irritation Diseases 0.000 claims description 2
229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims description 2
230000000694 effects Effects 0.000 claims description 2
230000001900 immune effect Effects 0.000 claims description 2
239000004530 micro-emulsion Substances 0.000 claims description 2
239000007764 o/w emulsion Substances 0.000 claims description 2
231100000475 skin irritation Toxicity 0.000 claims description 2
230000036556 skin irritation Effects 0.000 claims description 2
231100000046 skin rash Toxicity 0.000 claims description 2
210000001635 urinary tract Anatomy 0.000 claims description 2
102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 claims 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
108010002352 Interleukin-1 Proteins 0.000 claims 2
229910002651 NO3 Inorganic materials 0.000 claims 2
150000002500 ions Chemical class 0.000 claims 2
150000002696 manganese Chemical class 0.000 claims 2
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
229940127597 CGRP antagonist Drugs 0.000 claims 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
150000001206 Neodymium Chemical class 0.000 claims 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
102100024304 Protachykinin-1 Human genes 0.000 claims 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
239000003908 antipruritic agent Substances 0.000 claims 1
239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
229910021653 sulphate ion Inorganic materials 0.000 claims 1
239000007762 w/o emulsion Substances 0.000 claims 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 1
229910052748 manganese Inorganic materials 0.000 abstract 1
239000011572 manganese Substances 0.000 abstract 1
210000003491 skin Anatomy 0.000 description 33
239000006071 cream Substances 0.000 description 17
239000006210 lotion Substances 0.000 description 17
229910052747 lanthanoid Inorganic materials 0.000 description 16
150000002602 lanthanoids Chemical class 0.000 description 16
102400000096 Substance P Human genes 0.000 description 14
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 12
239000000499 gel Substances 0.000 description 10
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 7
229960002504 capsaicin Drugs 0.000 description 6
235000017663 capsaicin Nutrition 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
230000007803 itching Effects 0.000 description 6
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
235000013336 milk Nutrition 0.000 description 6
239000008267 milk Substances 0.000 description 6
210000004080 milk Anatomy 0.000 description 6
239000004094 surface-active agent Substances 0.000 description 6
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000002453 shampoo Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
239000002304 perfume Substances 0.000 description 4
239000012071 phase Substances 0.000 description 4
201000004700 rosacea Diseases 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
239000000344 soap Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
239000001993 wax Substances 0.000 description 4
208000002874 Acne Vulgaris Diseases 0.000 description 3
235000008733 Citrus aurantifolia Nutrition 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102000003141 Tachykinin Human genes 0.000 description 3
235000011941 Tilia x europaea Nutrition 0.000 description 3
206010000496 acne Diseases 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
230000008451 emotion Effects 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
235000019197 fats Nutrition 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
239000003349 gelling agent Substances 0.000 description 3
239000008233 hard water Substances 0.000 description 3
239000004310 lactic acid Substances 0.000 description 3
235000014655 lactic acid Nutrition 0.000 description 3
239000004571 lime Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
229960003471 retinol Drugs 0.000 description 3
235000020944 retinol Nutrition 0.000 description 3
239000011607 retinol Substances 0.000 description 3
229960004889 salicylic acid Drugs 0.000 description 3
210000004761 scalp Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
108060008037 tachykinin Proteins 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
201000004384 Alopecia Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
208000006877 Insect Bites and Stings Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
241001303601 Rosacea Species 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
102000009270 Tumour necrosis factor alpha Human genes 0.000 description 2
108050000101 Tumour necrosis factor alpha Proteins 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
229930003316 Vitamin D Natural products 0.000 description 2
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
239000013566 allergen Substances 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
230000000340 anti-metabolite Effects 0.000 description 2
229940100197 antimetabolite Drugs 0.000 description 2
239000002256 antimetabolite Substances 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
150000001805 chlorine compounds Chemical class 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
239000007957 coemulsifier Substances 0.000 description 2
238000004040 coloring Methods 0.000 description 2
230000008602 contraction Effects 0.000 description 2
239000002781 deodorant agent Substances 0.000 description 2
230000002951 depilatory effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000000975 dye Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
208000024963 hair loss Diseases 0.000 description 2
230000003676 hair loss Effects 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
229960004337 hydroquinone Drugs 0.000 description 2
150000001261 hydroxy acids Chemical class 0.000 description 2
230000007794 irritation Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229960003632 minoxidil Drugs 0.000 description 2
210000001640 nerve ending Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
150000002823 nitrates Chemical class 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
229950001046 piroctone Drugs 0.000 description 2
BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000004044 response Effects 0.000 description 2
229930002330 retinoic acid Natural products 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
230000036555 skin type Effects 0.000 description 2
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000000606 toothpaste Substances 0.000 description 2
229940034610 toothpaste Drugs 0.000 description 2
229960001727 tretinoin Drugs 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
230000002455 vasospastic effect Effects 0.000 description 2
235000019166 vitamin D Nutrition 0.000 description 2
239000011710 vitamin D Substances 0.000 description 2
150000003710 vitamin D derivatives Chemical class 0.000 description 2
229940046008 vitamin d Drugs 0.000 description 2
210000002268 wool Anatomy 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
HEAUFJZALFKPBA-JPQUDPSNSA-N (3s)-3-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-JPQUDPSNSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
206010050639 Allergic pharyngitis Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
108010087765 Antipain Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241001522729 Bassia <hydrozoan> Species 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
201000004813 Bronchopneumonia Diseases 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
102100038518 Calcitonin Human genes 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229920001076 Cutan Polymers 0.000 description 1
XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
206010015958 Eye pain Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
108010007979 Glycocholic Acid Proteins 0.000 description 1
MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
108010082786 Interleukin-1alpha Proteins 0.000 description 1
240000004101 Iris pallida Species 0.000 description 1
235000015265 Iris pallida Nutrition 0.000 description 1
208000006264 Korsakoff syndrome Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000008238 Muscle Spasticity Diseases 0.000 description 1
102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
206010051246 Photodermatosis Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
108010009736 Protein Hydrolysates Proteins 0.000 description 1
206010037083 Prurigo Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229920006243 acrylic copolymer Polymers 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229960003790 alimemazine Drugs 0.000 description 1
229960000458 allantoin Drugs 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
229940061720 alpha hydroxy acid Drugs 0.000 description 1
150000001280 alpha hydroxy acids Chemical class 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical class [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
230000003459 anti-dromic effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000001166 anti-perspirative effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
239000003213 antiperspirant Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
238000003287 bathing Methods 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
229940116224 behenate Drugs 0.000 description 1
UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
229960004311 betamethasone valerate Drugs 0.000 description 1
SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
208000010217 blepharitis Diseases 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
229940071162 caseinate Drugs 0.000 description 1
229940106189 ceramide Drugs 0.000 description 1
150000001783 ceramides Chemical class 0.000 description 1
ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
210000004240 ciliary body Anatomy 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
229960002291 clindamycin phosphate Drugs 0.000 description 1
229960004703 clobetasol propionate Drugs 0.000 description 1
CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
208000010247 contact dermatitis Diseases 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229960003338 crotamiton Drugs 0.000 description 1
DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
229940086555 cyclomethicone Drugs 0.000 description 1
JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
229960001140 cyproheptadine Drugs 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
230000035614 depigmentation Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
229940008099 dimethicone Drugs 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
230000037336 dry skin Effects 0.000 description 1
229960003913 econazole Drugs 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
229960003720 enoxolone Drugs 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
235000004626 essential fatty acids Nutrition 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
150000004673 fluoride salts Chemical class 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002315 glycerophosphates Chemical class 0.000 description 1
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000000118 hair dye Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
230000037189 immune system physiology Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000000554 iris Anatomy 0.000 description 1
150000004715 keto acids Chemical class 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
229960004705 kojic acid Drugs 0.000 description 1
WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
229960004393 lidocaine hydrochloride Drugs 0.000 description 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
150000004701 malic acid derivatives Chemical class 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000007383 nerve stimulation Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000019809 paraffin wax Nutrition 0.000 description 1
229940100460 peg-100 stearate Drugs 0.000 description 1
239000010702 perfluoropolyether Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
208000017983 photosensitivity disease Diseases 0.000 description 1
238000005498 polishing Methods 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
239000011252 protective cream Substances 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000001823 pruritic effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011775 sodium fluoride Substances 0.000 description 1
235000013024 sodium fluoride Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
208000018198 spasticity Diseases 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
159000000008 strontium salts Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000037072 sun protection Effects 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
229960002722 terbinafine Drugs 0.000 description 1
DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940043810 zinc pyrithione Drugs 0.000 description 1
PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/14—Preparations for removing make-up
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Immunology (AREA)
Birds (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO964517A 1995-10-26 1996-10-24 Anvendelse av et salt for fremstilling av et kosmetisk, dermatologisk eller farmasöytisk preparat, preparatet som sådan samt fremgangsmåte for kosmetisk behandling NO964517L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9512658A FR2740335B1 (fr)	1995-10-26	1995-10-26	Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p

Publications (2)

Publication Number	Publication Date
NO964517D0 NO964517D0 (no)	1996-10-24
NO964517L true NO964517L (no)	1997-04-28

Family

ID=9483959

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO964517A NO964517L (no)	1995-10-26	1996-10-24	Anvendelse av et salt for fremstilling av et kosmetisk, dermatologisk eller farmasöytisk preparat, preparatet som sådan samt fremgangsmåte for kosmetisk behandling

Country Status (9)

Country	Link
US (1)	US5900257A (de)
EP (1)	EP0770392B1 (de)
JP (1)	JP3112844B2 (de)
AT (1)	ATE300948T1 (de)
CA (1)	CA2188892C (de)
DE (1)	DE69635010T2 (de)
ES (1)	ES2246493T3 (de)
FR (1)	FR2740335B1 (de)
NO (1)	NO964517L (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6203803B1 (en)	1994-12-14	2001-03-20	Societe L'oreal S.A.	Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
WO1997009056A1 (fr) *	1995-09-07	1997-03-13	L'oreal	Extrait d'iridacees et compositions le contenant
AT405017B (de) *	1997-10-06	1999-04-26	Jakoby Marie Luise	Mittel zur stimulation der körpereigenen abwehr
IL133077A0 (en) *	1999-01-29	2001-03-19	Pfizer Prod Inc	Azithromycin combination for emesis control in dogs
JP2001139477A (ja) *	1999-11-17	2001-05-22	Coherent Technology:Kk	創傷部位の組織細胞増殖促進液
AU772029B2 (en) *	2000-03-08	2004-04-08	Sumika Enviro-Science Co., Ltd.	Method for denaturing allergens
FR2809006B1 (fr) *	2000-05-18	2002-08-02	Oreal	Utilisation du manganese dans des compositions destinees a combattre la paleur de la peau
FR2809005B1 (fr) *	2000-05-18	2002-12-27	Oreal	Utilisation du manganese dans le traitement des rides
AU2001282988B2 (en) *	2000-07-26	2006-01-05	Atopic Pty Ltd	Methods for treating atopic disorders
JP5140218B2 (ja)	2001-09-14	2013-02-06	有限会社コヒーレントテクノロジー	表面洗浄・表面処理に適した帯電アノード水の製造用電解槽及びその製造法、並びに使用方法
US20030059450A1 (en)	2001-09-24	2003-03-27	Maibach Howard I.	Method and topical formulation for treating skin conditions associated with aging
AU2002353060A1 (en) *	2001-12-05	2003-06-17	Oculus Innovative Sciences, Inc.	Method and apparatus for producing negative and positive oxidative reductive potential (orp) water
US7081247B2 (en) *	2002-05-20	2006-07-25	Nidaria Technology Ltd.	Composition and method for inhibiting polar capsule discharge and protecting a subject from nematocyst sting
US8404751B2 (en) *	2002-09-27	2013-03-26	Hallux, Inc.	Subunguicide, and method for treating onychomycosis
WO2004052326A1 (en) *	2002-12-09	2004-06-24	Evgeny Nikolaevich Ananiev	Pharmaceutical or cosmetic composition, preventing or reducing itch and local reaction from stings of insects
US6902723B2 (en) *	2003-08-14	2005-06-07	The Gillette Company	Enhanced efficacy antiperspirant compositions containing strontium
US6923952B2 (en) *	2003-08-14	2005-08-02	The Gillette Company	Enhanced efficacy antiperspirant compositions containing strontium or calcium
US20050196462A1 (en) *	2003-12-30	2005-09-08	Oculus Innovative Sciences, Inc.	Topical formulation containing oxidative reductive potential water solution and method for using same
US20050139808A1 (en) *	2003-12-30	2005-06-30	Oculus Innovative Sciences, Inc.	Oxidative reductive potential water solution and process for producing same
US9168318B2 (en)	2003-12-30	2015-10-27	Oculus Innovative Sciences, Inc.	Oxidative reductive potential water solution and methods of using the same
JP5528657B2 (ja) *	2003-12-30	2014-06-25	オキュラスイノヴェイティヴサイエンシズ、インコーポレイテッド	酸化還元電位水溶液並びにその製造方法および使用方法
US20080194487A1 (en) *	2005-01-12	2008-08-14	Witten Mark L	Treatment of Skin Diseases
WO2006102680A2 (en) *	2005-03-23	2006-09-28	Oculus Innovative Sciences, Inc.	Method of treating second and third degree burns using oxidative reductive potential water solution
JP5907645B2 (ja)	2005-05-02	2016-04-26	オキュラスイノヴェイティヴサイエンシズ、インコーポレイテッド	歯科用途における酸化還元電位水溶液の使用法
BRPI0706677A2 (pt) *	2006-01-20	2011-04-05	Oculus Innovative Sciences Inc	métodos de tratamento ou prevenção de sinusite com solução aquosa com potencial de oxirredução
JP2010501551A (ja) *	2006-08-25	2010-01-21	テウンイーエルエスインコーポレイテッド	毛髪改善のための希土類元素の用途
KR100818175B1 (ko)	2007-12-12	2008-04-02	주식회사 태웅이엘에스	모발처리용 조성물
JP2010200971A (ja) *	2009-03-03	2010-09-16	Hoyu Co Ltd	異常脱毛予測／推定方法、異常脱毛予防／防止方法及び異常脱毛防止剤評価方法
WO2010148004A1 (en)	2009-06-15	2010-12-23	Oculus Innovative Sciences, Inc.	Solution containing hypochlorous acid and methods of using same
DE102012110009A1 (de) *	2012-10-19	2014-04-24	Thomas Gniech	Mittel zur Linderung oder gegen Migräneschmerzen
EP4450058A3 (de) *	2012-12-27	2025-01-22	Jean-Claude Epiphani	Verfahren zur herstellung einer wässrigen emulsion eines ölhaltigen wirkstoffs zur kosmetischen, lebensmittel- oder pharmazeutischen anwendung
CN105377355A (zh)	2013-03-14	2016-03-02	拇趾公司	治疗甲单元的感染、疾病或病症的方法
FR3031677B1 (fr) *	2015-01-16	2019-06-07	L'oreal	Composition cosmetique pour administration par voie topique pour renforcer la barriere cutanee.
WO2020091699A1 (en)	2018-10-31	2020-05-07	Yeditepe Universitesi	Use of nano-sized lanthanide borate (dysprosium borate and erbium borate) compounds for wound healing purposes and production method thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE297062C (de) *
GB997975A (en) *	1964-01-31	1965-07-14	Aristotelis Papageorgiou Lambo	Pharmaceutical compositions containing a cresol or a mixture of cresols
GB1072355A (en) *	1964-06-17	1967-06-14	Michael Collin	Antiseptic and anti-pruretic solution containing camphor
US3519711A (en) *	1967-09-01	1970-07-07	Robert E Svigals	Composition and method of treating pruritic conditions of the skin
IE35991B1 (en) *	1971-01-22	1976-07-21	Comprehensive Pharmaceuticals	Improvements in or relating to the treatment of diseases of the skin and mucosa
LU65373A1 (de) *	1972-05-17	1973-11-23
US3888976A (en) *	1972-09-21	1975-06-10	William P Mlkvy	Zinc and strontium ion containing effervescent mouthwash tablet
US3772431A (en) *	1972-09-21	1973-11-13	W Mlkvy	Effervescent mouthwash tablet
DE2715711A1 (de) *	1977-04-07	1978-10-19	Robugen Gmbh	Topisch anwendbares arzneimittel zur behandlung von viruserkrankungen der haut und der schleimhaut
DE3030215A1 (de) *	1980-08-09	1982-03-18	Bergwerksverband Gmbh, 4300 Essen	Wirbelbett-feuerung
US4477439A (en) *	1981-04-13	1984-10-16	Walter J. Monacelli	Treatment of irritated and excoriated areas around the stoma of ostomy patients
WO1983001252A1 (en) *	1981-10-09	1983-04-14	Hakanson, Rolf	A drug based on a substance p antagonist
AU556817B2 (en) *	1982-02-03	1986-11-20	Efamol Limited	Topical application of a lithium salt and dihomo-alpha- linolenic acid
GB8320203D0 (en) *	1983-07-27	1983-09-01	Horrobin D F	Anti-viral compositions
DE3338957A1 (de) *	1983-10-27	1985-05-15	Keyhan Dipl.-Ing. 6908 Wiesloch Ghawami	Enthaarungsmittel
DE3443985A1 (de) *	1984-12-01	1986-06-05	Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen	Arzneimittelzubereitungen gegen mykotische und bakterielle infektionen mit einem gehalt an wirkstoffen, welche zink in ionisierter form freisetzen
IT1214611B (it) *	1985-05-22	1990-01-18	Schiena Ricerche	Composti per uso cosmetico dermatologico e relative composizioni.
US4837026A (en) *	1985-10-03	1989-06-06	Rajakhyaksha Vithal J	Transdermal and systemic preparation and method
EP0217975B1 (de) *	1985-10-08	1991-12-04	Psori-Med Ag	Salzmischung zur Behandlung der Schuppenflechte (Psoriasis) und anderer Hautkrankheiten
US4735802A (en) *	1986-05-05	1988-04-05	Le Bich N	Topical dermatological composition and method of treatment
FR2599967B1 (fr) *	1986-06-16	1989-03-31	Bfb Etudes Rech Experimentale	Utilisation de sel de zinc et de la vitamine b6 pour enrayer les processus alopeciques et/ou seborrheiques.
US4986981A (en) *	1986-07-07	1991-01-22	Den Mat Corporation	Toothpaste having low abrasion
US5091171B2 (en) *	1986-12-23	1997-07-15	Tristrata Inc	Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
SE8701372L (sv) *	1987-04-02	1988-10-03	Boliden Ab	Foerfarande och medel foer konservering av hoe
AU616502B2 (en) *	1988-04-22	1991-10-31	Medvet Science Pty. Ltd.	Treatment of inflammatory disorders in humans
DE3929411A1 (de) *	1988-09-22	1990-03-29	Siegfried Natterer	Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
US4938969A (en) *	1988-11-14	1990-07-03	Milor Scientific, Ltd.	Method for the treatment of aging or photo-damaged skin
CA2014201A1 (en) *	1989-04-26	1990-10-26	Albemarle Corporation	Solid non-hygroscopic trialkylamine oxides
GB8916625D0 (en) *	1989-07-20	1989-09-06	Bryce Smith Derek	Respiratory tract spray preparations
SU1679008A1 (ru) *	1989-07-26	1991-09-23	Производственно Промышленное Объединение "Железобетон"	Арматурный элемент дл дисперсного армировани бетона
US5202130A (en) *	1989-08-31	1993-04-13	The Johns Hopkins University	Suppression of eczematous dermatitis by calcium transport inhibition
US5296476A (en) *	1989-09-08	1994-03-22	Henderson Esther G	Skin care compositions
DE59002748D1 (de) *	1990-01-29	1993-10-21	Wogepharm Gmbh	Verfahren zur Herstellung von Mitteln zur Therapie von Hauterkrankungen.
EP0451300B1 (de) *	1990-04-10	1994-10-26	Romuald Dr. Kowalski	Bariumsulfat-kolloidale Dispersion enthaltende Zusammensetzung
US5401730A (en) *	1990-07-06	1995-03-28	The Hope Heart Institute	Method for reducing platelet aggregation
AU664188B2 (en) *	1991-07-05	1995-11-09	Merck Sharp & Dohme Limited	Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
WO1993001165A2 (en) *	1991-07-10	1993-01-21	Merck Sharp & Dohme Limited	Aromatic compounds, compositions containing them and their use in therapy
RU2038072C1 (ru) *	1991-11-01	1995-06-27	Государственный российский научно-исследовательский институт органической химии и технологии	Крем для защиты кожи от химических веществ и способ его получения
GB9201179D0 (en) *	1992-01-21	1992-03-11	Glaxo Group Ltd	Chemical compounds
DE69334068D1 (de) *	1992-07-20	2006-11-16	Massachusetts Inst Technology	Kontrolle der wundvernarbung mit calmodulin-inhibitoren oder protein-kinase-c-inhibitoren
DE4227203C2 (de) *	1992-08-17	1994-03-24	Kao Corp Gmbh	Mittel und Verfahren zur Haarbehandlung
GB9222486D0 (en) *	1992-10-26	1992-12-09	Merck Sharp & Dohme	Therapeutic agents
WO1994009798A1 (en) *	1992-10-29	1994-05-11	C-P Technology Limited Partnership	Mixtures or complexes containing calcium and sulfate
US5716625A (en) *	1994-12-21	1998-02-10	Cosmederm Technologies	Formulations and methods for reducing skin irritation
US6455076B1 (en) *	1994-12-21	2002-09-24	Gary S. Hahn	Formulations and methods for reducing skin irritation
EP0799018A4 (de) *	1994-12-21	2000-03-29	Cosmederm Technologies	Formulierungen und verfahren zur verminderung von hautirritationen

1995
- 1995-10-26 FR FR9512658A patent/FR2740335B1/fr not_active Expired - Fee Related
1996
- 1996-10-14 DE DE69635010T patent/DE69635010T2/de not_active Expired - Lifetime
- 1996-10-14 ES ES96402182T patent/ES2246493T3/es not_active Expired - Lifetime
- 1996-10-14 AT AT96402182T patent/ATE300948T1/de not_active IP Right Cessation
- 1996-10-14 EP EP96402182A patent/EP0770392B1/de not_active Expired - Lifetime
- 1996-10-24 NO NO964517A patent/NO964517L/no unknown
- 1996-10-25 CA CA002188892A patent/CA2188892C/fr not_active Expired - Fee Related
- 1996-10-25 JP JP08284318A patent/JP3112844B2/ja not_active Expired - Fee Related
- 1996-10-28 US US08/738,811 patent/US5900257A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO964517D0 (no)	1996-10-24
JP3112844B2 (ja)	2000-11-27
JPH09165341A (ja)	1997-06-24
EP0770392A3 (de)	1997-05-07
EP0770392B1 (de)	2005-08-03
FR2740335B1 (fr)	1997-12-19
ES2246493T3 (es)	2006-02-16
CA2188892C (fr)	2008-06-17
DE69635010T2 (de)	2006-04-20
US5900257A (en)	1999-05-04
ATE300948T1 (de)	2005-08-15
FR2740335A1 (fr)	1997-04-30
CA2188892A1 (fr)	1998-04-25
EP0770392A2 (de)	1997-05-02
DE69635010D1 (de)	2005-09-08

Publication	Publication Date	Title
US5900257A (en)	1999-05-04	Cosmetic/pharmaceutical compositions comprising lanthanide manganese, tin and/or yttrium salts as substance P antagonists
US5866168A (en)	1999-02-02	Dermatological/pharmaceutical compositions comprising lanthanide, manganese, tin, zinc, yttrium, cobalt, barium and/or strontium salts as substance P antagonists
RU2188029C2 (ru)	2002-08-27	Применение экстракта из нефотосинтезирующей нитчатой бактерии и содержащая его композиция
US6262050B1 (en)	2001-07-17	Topical composition containing capsazepine
US6019967A (en)	2000-02-01	Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
US5851556A (en)	1998-12-22	Use of a salt of an alkaline-earth metal as TNF-A or substance P inhibitor in a topical composition and composition obtained
JP3093154B2 (ja)	2000-10-03	アヤメ科植物抽出物及びそれを含む組成物
JP3110050B2 (ja)	2000-11-20	敏感肌の治療における少なくとも１つのｎｏシンターゼ阻害剤の使用
US20010014342A1 (en)	2001-08-16	Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US6241993B1 (en)	2001-06-05	Therapeutic/cosmetic compositions comprising bradykinin antagonists for treating sensitive human skin
US20100004311A1 (en)	2010-01-07	Excitatory amino acid inhibitors for treating sensitive skins
RU2169552C2 (ru)	2001-06-27	ПРИМЕНЕНИЕ ПО МЕНЬШЕЙ МЕРЕ ОДНОГО β-АДРЕНЕРГИЧЕСКОГО АГОНИСТА В КАЧЕСТВЕ АНТАГОНИСТА ВЕЩЕСТВА Р
US20120172446A1 (en)	2012-07-05	L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin
US5968532A (en)	1999-10-19	Use of an ethylenediamine derivative in a cosmetic or dermatological composition containing in particular a product having an irritant side effect
US6416760B2 (en)	2002-07-09	Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
US6106846A (en)	2000-08-22	Use of at least one thermal spring water from Vichy as a substance P antagonist